Non-synergy of PD-1 blockade with T-cell therapy in solid tumors

BACKGROUND: Cell therapy has shown promise in the treatment of certain solid tumors, but its efficacy may be limited by inhibition of therapeutic T cells by the programmed cell death protein-1 (PD-1) receptor. Clinical trials are testing cell therapy in combination with PDCD1 disruption or PD-1-axis...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, John S, Karimipour, Farrah, Zhang, Ling, Nagarsheth, Nisha, Norberg, Scott, Serna, Carylinda, Strauss, Julius, Chiou, Shinheng, Gulley, James L, Hinrichs, Christian S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260838/
https://www.ncbi.nlm.nih.gov/pubmed/35793866
http://dx.doi.org/10.1136/jitc-2022-004906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260838/
https://www.ncbi.nlm.nih.gov/pubmed/35793866
http://dx.doi.org/10.1136/jitc-2022-004906

Ejemplares similares